Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Maithreyan Srinivasan"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/c97d93e9fe1f4274909ed379614db689
Autor:
Anushka Dikshit, Li-Chong Wang, Ge-Ah Kim, Sonali Deshpande, Maithreyan Srinivasan, Julia Yu, Laetitia Chatelain, Nancy George
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/8d110b3102054d61a3bdb53281842df6
Autor:
Steve Zhou, Li-Chong Wang, Ge-Ah Kim, Sonali Deshpande, Maithreyan Srinivasan, Laetitia Chatelain, Nancy George, Anji Bei
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/48fae73e7d1f40f3bbb484a5d4635c11
Autor:
Ruli Gao, Charissa Kim, Emi Sei, Theodoros Foukakis, Nicola Crosetto, Leong-Keat Chan, Maithreyan Srinivasan, Hong Zhang, Funda Meric-Bernstam, Nicholas Navin
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-12 (2017)
Single cell RNA sequencing is a powerful tool for understanding cellular diversity but is limited by cost, throughput and sample preparation. Here the authors use nanogrid technology with integrated imaging to sequence thousands of cancer nuclei in p
Externí odkaz:
https://doaj.org/article/830f1e7e517147f0b71c9f627efb4d1b
Autor:
Leonard D. Goldstein, Ying-Jiun Jasmine Chen, Jude Dunne, Alain Mir, Hermann Hubschle, Joseph Guillory, Wenlin Yuan, Jingli Zhang, Jeremy Stinson, Bijay Jaiswal, Kanika Bajaj Pahuja, Ishminder Mann, Thomas Schaal, Leo Chan, Sangeetha Anandakrishnan, Chun-wah Lin, Patricio Espinoza, Syed Husain, Harris Shapiro, Karthikeyan Swaminathan, Sherry Wei, Maithreyan Srinivasan, Somasekar Seshagiri, Zora Modrusan
Publikováno v:
BMC Genomics, Vol 18, Iss 1, Pp 1-10 (2017)
Abstract Background Technological advances have enabled transcriptome characterization of cell types at the single-cell level providing new biological insights. New methods that enable simple yet high-throughput single-cell expression profiling are h
Externí odkaz:
https://doaj.org/article/0f2cc86fd322428794946fd046b7a06a
Autor:
Anushka Dikshit, Sayantani Basak, Sonali Deshpande, Manvir Sambhi, Li-Chong Wang, Maithreyan Srinivasan
Publikováno v:
Cancer Research. 83:3775-3775
Regulatory RNA molecules such as microRNAs (miRNA) and long non-coding RNAs play critical roles in regulating translation of mRNA to protein. Several miRNAs have been implicated in disease initiation and progression, especially in cancer. The regulat
Autor:
Niyati Jhaveri, HaYeun Ji, Anushka Dikshit, Jessica Yuan, Emerald Doolittle, Steve Zhou, Maithreyan Srinivasan, Bassem B. Cheikh, Fabian Schneider, James Mansfield, Julia Kennedy-Darling, Oliver Braubach
Publikováno v:
Cancer Research. 83:5626-5626
Background: It has been well established that the tumor microenvironment (TME), which comprises cancer cells, stromal cells, and surrounding extracellular matrix, plays a critical role in cancer development, progression, and control. The immunologica
Autor:
Anushka Dikshit, Sayantani Basak, Vasudha Murlidhar, Ge-Ah Kim, Julia Yu, Sonali Deshpande, Li-Chong Wang, Maithreyan Srinivasan
Publikováno v:
Cancer Research. 83:6771-6771
Understanding tissue heterogeneity is critical for elucidating cell-cell interactions with important implications in immuno-oncology, inflammation, and neuroscience. Tissue heterogeneity poses immense challenges to understanding underlying molecular
Autor:
Justin L. Madrigal, Nathan G. Schoepp, Linfeng Xu, Codian S. Powell, Cyrille L. Delley, Christian A. Siltanen, Jay Danao, Maithreyan Srinivasan, Russell H. Cole, Adam R. Abate
Publikováno v:
Proceedings of the National Academy of Sciences of USA, vol 119, iss 5
Cell-cell interactions are important to numerous biological systems, including tissue microenvironments, the immune system, and cancer. However, current methods for studying cell combinations and interactions are limited in scalability, allowing just
Publikováno v:
Cancer Research. 80:133-133
NCI estimates that cancer will be the leading cause of death in 2030, worldwide. Checkpoint inhibitors and adoptive cell therapies (ACTs) cost up to ~$2 million/patient and have shown durable responses in a few patients while many patients experience